Inhibition of Tumor Growth and Metastasis by an Immunoneutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor/Vascular Permeability Factor121

Cancer Research

Volumn 55, Issue 22, 1995, Pages 5296-5301

  Asano, Makoto ^a   Yukita, Ayako ^a   Matsumoto, Tomoe ^a   Kondo, Shinichi ^a   Suzuki, Hideo ^a  

^a Base Technology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SOLID TUMOR; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VOLUME;

ANIMAL; ANTIBODIES, MONOCLONAL; CELL DIVISION; CELL LINE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMAN; LYMPHOKINES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0028824336     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175–203, 1985.
2. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4–6, 1990.
3. Folkman, J., and Klagsbrun, M. Angiogenic factors. Science (Washington DC), 235: 442–447, 1987.
4. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217–239, 1991.
5. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931–10934, 1992.
6. Thomas, K. A., Rios-Candelore, M., Gimenez-Gallego, G., DiSalvo, J., Bennett, C., Rodkey, J., and Fitzpatrick, S. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin-1. Proc. Natl. Acad. Sci. USA, 82: 6409–6413, 1985.
7. Montesano, R., Vassalli, J.-D., Baird, A., Guillemin, R., and Orci, L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA, 83: 7297–7301, 1986.
8. Gospodarowicz, D., Ferrara, N., Schweigerer, L., and Neufeld, G. Structural characterization and biologic function of fibroblast growth factor. Endocr. Rev., 8: 95–114, 1987.
9. Schreiber, A. B., Winker, M. E., and Derynck, R. Transforming growth factor-cr: a more potent angiogenic mediator than epidermal growth factor. Science (Washington DC), 232: 1250–1253, 1986.
10. Robert, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Rosch, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V., Kehrl, J. H., and Fauci, A. S. Transforming growth factor type 0: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA, 84: 4167–4171, 1986.
11. Fett, J. W., Strydom, D. J., Lobb, R. R., Alderman, E. M., Bethune, J. L., Riordanm, J. F., and Vallee, B. L. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry, 24: 5480–5486, 1985.
12. Hockel, M., Jung, W., Vaupel, P., Rabes, H., Khaledpour, C., and Wissler, J. W. Purified monocyte-derived angiogenic substance (angiotropin) induces controlled angiogenesis associated with regulated tissue proliferation in rabbit skin. J. Clin. Invest., 82: 1075–1090, 1988.
13. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-a. Nature (Lond.), 329: 631–832, 1987.
14. Frater-Schroder, M., Risau, W., Hallmann, R., Gautschi, R., and Bohlen, P. Tumor necrosis factor type-a, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA, 84: 5277–5281, 1987.
15. Miyazono, K., Okabe, T., Urabe, A., Takaku, F., and Heldin, C.-H. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem., 262: 4098–4103, 1987.
16. Ishikawa, F., Miyazono, K., Hellman, U., Hannes, D., Wernstadt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C.-H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (Lond.), 338: 557–562, 1989.
17. Ferrara, N., and Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Com-mun., 161: 851–858, 1989.
18. Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306–1309, 1989.
19. Conn, G., Soderman, D., Schaeffer, M.-T., Wile, M., Hatcher V. B., and Thomas, K. A. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma cell line. Proc. Natl. Acad. Sci. USA, 87: 1323–1327, 1990.
20. Tisher, E., Gospodarowicz, D., Mitchell, R., Silva, M., Schilling, J., Lau, K., Crisp, T., Fiddes, J. C., and Abraham, J. A. Vascular endothelial growth factor: a new member of the platelet derived growth factor gene family. Biochem. Biophys. Res. Commun., 165: 1198–1206, 1989.
21. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983–985, 1983.
22. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connoly, D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC), 246: 1309–1312, 1989.
23. Connoly, D. T., Hauvelman, D. M., Nelson, R., Holander, J. V., Eppley, B. L., Delfmo, J. J., Siegel, R. N., Leimgruber, R. S., and Feder, J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest., 84: 1470–1478, 1989.
24. Connoly, D. T. Vascular permeability factor: a unique regulator of blood vessel function. J. Cell. Biochem., 47: 219–223, 1991.
25. Plouet, J., Schilling, J., and Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J., 8: 3801–3806, 1989.
26. Favard, C., Moukadiri, H., Dorey, C., Praloran, V., and Plouet, J. Purification and biological properties of vasculotropin, a new angiogenic cytokine. Biol. Cell, 73:1–6, 1991.
27. Vaisman, N., Gospodarowicz, D., and Neufeld, G. Characterization of the receptor for vascular endothelial growth factor. J. Biol. Chem., 265: 19461–19466, 1990.
28. Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. Nucleotide sequence and expression of novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene, 5: 519–524, 1990.
29. Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L., and Shows, T. B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 6: 1677–1683, 1991.
30. de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (Washington DC), 255: 989–991, 1992.
31. Terman, B. I., Vermazen, M. D., Carrion, M. E., Dimitrov, D., Armellino, D. T., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579–1585, 1992.
32. Senger, D. R., Perruzzi, C. A., Feder, J., and Dvorak, H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res., 46: 5629–5632, 1986.
33. Connoly, D. T., Olander, J. V., Heuvelman, D., Nelson, R., Monsell, R., Siegel, N., Haymore, B. L., Leimgruber, R., and Feder, J. Human vascular permeability factor. J. Biol. Chem., 264: 20017–20024, 1989.
34. Myoken, Y., Kayada, Y., Okamoto, T., Kan, M., Sato, G. H., and Sato, J. D. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc. Natl. Acad. Sci. USA, 88: 5819–5823, 1991.
35. Kondo, S., Asano, M., and Suzuki, H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth and its inhibition by the antibody. Biochem. Biophys. Res. Commun., 194: 1234–1241, 1993.
36. Kondo, S., Asano, M., Matsuo, K., Ohmori, I., and Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta, 7227: 211–214, 1994.
37. Yeo, K.-T., Wang, H. H., Nagy, J. A., Sioussat, T. M., Ledbetter, S. R., Hoogewerf, A. J., Zhou, Y., Masse, E. M., Senger, D. R., Dvorak, H. F., and Yeo, T.-K. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res., 53: 2912–2918, 1993.
38. Kim, J., Li, B., Winer, J., Armaninim, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 262: 841–844, 1993.
39. Blood, C. H., and Zetter, B. R. Tumor interactions with the vasculature: angiogenesis and metastasis. Biochim. Biophys. Acta, 1032: 89–118, 1990.
40. Kondo, S., Matsumoto, T., Yokoyama, Y., Ohmori, I., and Suzuki, H. The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF,2i) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability. Biochim. Biophys. Acta, 1243: 195–202, 1995.
41. Asano, M., Yukita, A., Matsumoto, T., Matsuo, K., Kondo, S., and Suzuki, H. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121). Hybri-doma, 14: 475–480, 1995.
42. Greenwood, F. C., Hunter, W. H., and Glover, J. S. 125I-labeled growth hormone of high specific radioactivity. Biochem. J., 89: 114–123, 1963.
43. Tanaka, N., Sakamoto, N., Inoue, K., Korenaga, H., Kadoya, S., Ogawa, H., and Osada, Y. Antitumor effect of an antiangiogenic polysaccharide from an Arthrobactor species with or without a steroid. Cancer Res., 49: 6727–6730, 1989.
44. Tischer, E., Mitchell, R., Hartman, T., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. The human gene for vascular endothelial growth factor. J. Biol. Chem., 266: 11947–11954, 1991.
45. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., and Leung, D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol., 5: 1806–1814, 1991.
46. Waltenberger, J., Welsh, L. C., Siegbahnm, A., Shibuya, M., and Heldin, C. H. Different signal transduction properties of KDR and Flt-1, two receptor for vascular endothelial growth factor. J. Biol. Chem., 269: 26988–26995, 1994.
47. Gospodarowicz, D., Neufeld, G., and Schweigerer, L. Fibroblast growth factor. Mol. Cell. Endocrinol., 46: 187–204, 1986.
48. Takahashi, J. A., Fukumoto, M., Kozai, Y., Ito, N., Oda, Y., Kikuchi, H., and Hatanaka, M. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett., 288: 65–71, 1991.
49. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 51: 6180–6184, 1991.
50. Baird, A., Mormede, P., and Bohlen, P. Immunoreactive fibroblast growth factor (FGF) in a transplantable chondorosarcoma: inhibition of tumor growth by antibodies to FGF. J. Cell. Biochem., 30: 79–85, 1986.
51. Matsuzaki, K., Yoshitake, Y., Matsuo, H., Sasaki, K., and Nishikawa, K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc. Natl. Acad. Sci. USA, 86: 9911–9915, 1989.
52. Dennis, P. A., and Rifkin, D. B. Studies on the role of basic fibroblast growth factor in vivo. Inability of neutralizing antibodies to block tumor growth. J. Cell. Physiol., 144: 84–98, 1990.
53. Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., and Ferrara, N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest., 95: 1789–1797, 1995.